Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Azizi

Showing results (191-200 of 267) with videos related to

Pageof 27
Sort By:
Journal of the American Heart Association|May 17, 2021
Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular DysplasiaCharlotte Arnaud, Marion Boulanger, Aurélien Lorthioir, et al.
Journal of Hypertension|November 7, 2014
Hyperresponders vs. nonresponder patients after renal denervation: do they differ?Alexandre Persu, Michel Azizi, Yu Jin, et al.
Lancet (London, England)|January 30, 2015
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trialMichel Azizi, Marc Sapoval, Philippe Gosse, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension (Dallas, Tex. : 1979)|November 5, 2021
Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence TestingDan Lane, Alexander Lawson, Angela Burns, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Pharmacoeconomics - Open|May 8, 2024
Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant HypertensionRod S Taylor, Anthony Bentley, Kaylie Metcalfe, et al.
Pharmacoeconomics - Open|January 30, 2024
Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant HypertensionRod S Taylor, Anthony Bentley, Kaylie Metcalfe, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|October 8, 2021
Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO TrialKintur Sanghvi, Yale Wang, Joost Daemen, et al.
Lancet (London, England)|November 5, 2015
The double challenge of resistant hypertension and chronic kidney diseasePatrick Rossignol, Ziad A Massy, Michel Azizi, et al.
Pageof 27

Showing results (191-200 of 267) with videos related to

Sort By:
Pageof 27
Journal of the American Heart Association|May 17, 2021
Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular DysplasiaCharlotte Arnaud, Marion Boulanger, Aurélien Lorthioir, et al.
Journal of Hypertension|November 7, 2014
Hyperresponders vs. nonresponder patients after renal denervation: do they differ?Alexandre Persu, Michel Azizi, Yu Jin, et al.
Lancet (London, England)|January 30, 2015
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trialMichel Azizi, Marc Sapoval, Philippe Gosse, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension (Dallas, Tex. : 1979)|November 5, 2021
Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence TestingDan Lane, Alexander Lawson, Angela Burns, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Pharmacoeconomics - Open|May 8, 2024
Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant HypertensionRod S Taylor, Anthony Bentley, Kaylie Metcalfe, et al.
Pharmacoeconomics - Open|January 30, 2024
Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant HypertensionRod S Taylor, Anthony Bentley, Kaylie Metcalfe, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|October 8, 2021
Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO TrialKintur Sanghvi, Yale Wang, Joost Daemen, et al.
Lancet (London, England)|November 5, 2015
The double challenge of resistant hypertension and chronic kidney diseasePatrick Rossignol, Ziad A Massy, Michel Azizi, et al.
Pageof 27